A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment

Modern Rheumatology

Volumn 27, Issue 3, 2017, Pages 536-540

  Koichi, Yamaguchi ^a   Aya, Yamaguchi ^a   Megumi, Uchida ^a   Shunichi, Kono ^a   Masafumi, Suzuki ^a   Hiroaki, Masubuchi ^a   Masahiko, Kanbe ^a   Shinsuke, Kitahara ^a   Manabu, Ueno ^a   Kenichiro, Hara ^a   Fumiaki, Aoki ^a   Nozomi, Aoki ^a   Toshitaka, Maeno ^a   Masayoshi, Yamanaka ^a   Chikako, Kishi ^a   Yoshinao, Muro ^b   Tatsuo, Suga ^a   Masahiko, Kurabayashi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti MDA5 antibody; Dermatomyositis; Interstitial lung disease; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; CYCLOPHOSPHAMIDE; FERRITIN; FLUORODEOXYGLUCOSE F 18; FRUCTOSE BISPHOSPHATE ALDOLASE; GANCICLOVIR; IMMUNOGLOBULIN; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; LACTATE DEHYDROGENASE; POLYMYXIN B; PREDNISOLONE; RITUXIMAB; TACROLIMUS; VALGANCICLOVIR; VORICONAZOLE; IFIH1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

AGED; ARTICLE; ASPERGILLUS; BLOOD GAS ANALYSIS; CASE REPORT; DERMATOMYOSITIS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LOSS OF APPETITE; MILD HEPATIC IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; SKIN BIOPSY; X-RAY COMPUTED TOMOGRAPHY; COMPLICATION; IMMUNOLOGY;

AGED; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-INDUCED HELICASE, IFIH1; LUNG DISEASES, INTERSTITIAL; RITUXIMAB;

EID: 85018750966     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1014140     Document Type: Article

References (20)

1. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of adult-onset clinically-amyopathic dermatomyositis (syn. dermatomyositis sine myositis):a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597–613.
2. Tokiyama K, Tagawa H, Yokota E, Nagasawa K, Kusaba T, Tsuda Y, Niho Y. Two cases of amyopathic dermatomyositis with fatal rapidly progressive interstitial pneumonitis. Ryumachi. 1990;30(3):204–11.
3. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433–40.
4. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology(Oxford). 2012;51(9):1563–70.
5. Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011;30(8):1021–28.
6. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005; 32(9):1719–26.
7. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136(5):1341–7.
8. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140):a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.
9. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012; 51(5):800–4.
10. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013;107(5):745–52.
11. Nagasaka K, Harigai M, Tateishi M, Hara M, Yoshizawa Y, Koike T, Miyasaka N. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Modern Rheumatol. 2003; 13(3):231–8.
12. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease:a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38(5):383–92.
13. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353–59.
14. Marie I, Dominiqueb S, Janvressec A, Levesquea H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106(4):581–87.
15. Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, et al. Severe interstitial lung disease in connective tissue disease:rituximab as rescue therapy. Eur Respir J. 2012;40(3):641–48.
16. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.
17. Tristano AG. Macrophage activation syndrome:a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Moint. 2008;14(3):27–36.
18. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110(8):2924–30.
19. Clottu A, Laffitte E, Prins C, Chizzolini C. Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology. 2012;225(4):376–80.
20. Girard C, Vincent T, Bessis D. Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies:an atypical case. Ann Dermatol Venereol. 2013;140(10):628–34.